T2 Biosystems to Report Second Quarter 2022 Financial Results on August 15, 2022
T2 Biosystems (NASDAQ:TTOO) will announce its second quarter 2022 financial results after market close on August 15, 2022. The announcement will be followed by a conference call at 4:30 p.m. ET, accessible via a live and archived webcast on the company's website. T2 Biosystems specializes in rapid detection of sepsis-causing pathogens and antibiotic resistance, aiming to enhance patient care while minimizing treatment costs. Their product lineup includes the T2Dx Instrument and various detection panels, backed by their proprietary T2 Magnetic Resonance technology.
- Continued innovation in sepsis detection technology.
- Strong product lineup aimed at improving patient care.
- Active pipeline for future products, enhancing growth potential.
- None.
LEXINGTON, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. The call will also be available by dialing 1-844-825-9789 (U.S.) or 1-412-317-5180 (International) five to ten minutes prior to the start time.
About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Bacteria® Panel, T2Candida® Panel, T2Resistance® Panel, and T2SARS-CoV-2™ Panel and are powered by the Company’s proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat™ Panel, T2Cauris™ Panel, T2Lyme™ Panel, and new products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406
FAQ
When will T2 Biosystems report its Q2 2022 earnings?
How can I listen to the T2 Biosystems earnings call?
What is the focus of T2 Biosystems?
What products does T2 Biosystems offer?
What technology powers T2 Biosystems’ products?
